Lord Hunt of Kings Heath: To ask His Majesty's Government, further to the Written Answer by Lord Markham on 9 February (HL5209), why the Gloucestershire Integrated Care Board continues to re-review liothyronine patients already assessed in the NHS despite national guidance that “patients who have already had a review by an NHS consultant endocrinologist should continue to be prescribed liothyronine under existing...
Lord Hunt of Kings Heath: To ask His Majesty's Government what plans they have to review Gloucestershire Integrated Care Board’s (ICB) policy on liothyronine to assess the extent to which it (1) follows national guidance, by asking new patients who have already been reviewed by specialist NHS consultants to be reviewed again if they move into Gloucestershire from another ICB area, and (2) incurs higher costs and...
Lord Hunt of Kings Heath: To ask His Majesty's Government what cost assessment they have undertaken of the daily dose rationing of liothyronine regardless of clinical need by the (1) NHS Devon, (2) NHS Buckinghamshire, and (3) NHS Hertfordshire, Integrated Care Boards; and what comparative assessment they have made of (a) the NHS England national guidance, and (b) the National Institute for Health and Care Excellence...
Lord Hunt of Kings Heath: To ask His Majesty's Government what assessment they have made of the NHS costs incurred by sending thyroid patients to secondary care for liothyronine, given NHS England national guidance only requires initiation of treatment in secondary care but allows regular prescribing in primary care.
Darren Jones: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of expanding access to the drug Liothyronine T3 for people with hypothyroidism.
Lord Hunt of Kings Heath: To ask His Majesty's Government what alternative medicine will be made available to patients for the treatment of hypothyroidism in the event that (1) Liothyronine (T3), and (2) Levothyroxine (T4), medications prove to be ineffective.
Richard Foord: To ask the Secretary of State for Health and Social Care, What steps he has taken to improve access to Liothyronine (T3) for the treatment of hypothyroidism?
Thyroid Patients: Liothyronine - Question
Justin Madders: ...has had discussions with relevant stakeholders on reviewing prescription guidelines following the decision by the Competition and Markets Authority to fine Advanz for the inflation of the price of Liothyronine.
Lord Callanan: The Competition and Markets Authority’s decisions in respect of liothyronine and hydrocortisone tablets are subject to appeals to the Competition Appeal Tribunal. It would not be appropriate for the Government to comment on the matter while these legal proceedings are ongoing.
Lord Kamall: .... It is the responsibility of the regulators to determine what specific role they should play in raising awareness of rare and less common conditions. On—and I apologise if I mispronounce this—liothyronine and the power of direction, the NICE guideline on the assessment and management of thyroid disease, as the noble Lord acknowledged, does not recommend liothyronine for primary...
Justin Madders: ...he has had with relevant stakeholders on reviewing prescription guidelines following the decision by the Competition and Markets Authority to fine Advanz for the inflation of the price of Liothyronine.
Lord Hunt of Kings Heath: To ask Her Majesty's Government whether they will conduct a review of (1) the actions of NHS England, and (2) the impact on patients with thyroid conditions, following the Competition and Markets Authority’s ruling and fine issued to Advanz for artificially inflating the price of thyroid tablets.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what steps NHS Clinical Commissioners took to communicate national guidance for the prescribing of liothyronine to local NHS bodies; and whether that guidance says that liothyronine may only be prescribed when recommended by a specialist after treatment using levothyroxine has failed.
Lord Hunt of Kings Heath: To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 17 March (HL14040), what assessment they have made as to whether the fall in the price of Liothyronine (T3) is related to increased competition from marketing authorisations granted since 2016.
Lord Hunt of Kings Heath: ...by the Competition and Markets Authority that drug companies had over-charged the National Health Service, what plans they have to reduce the price that the National Health Service pays for liothyronine.
Lord Hunt of Kings Heath: To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 4 March (HL13668), what comparison they have made of the cost of Liothyronine (T3) in (1) the UK, and (2) EU member states; and what assessment they have made of any such comparison.
Lord Hunt of Kings Heath: ..., further to the Written Answer by Lord Bethell on 17 February (HL13177), whether an intervention under the Health Service Medical Supplies (Costs) Act 2017 has taken place to control the cost of Liothyronine (T3); and if not, why not.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what progress they have made in reducing the price charged for Liothyronine (T3).